Gilead Sciences Inc Stock
Price
Target price
€116.00
€116.00
0.870%
1.0
0.870%
€120.64
26.01.26 / Tradegate
WKN: 885823 / Symbol: GILD / Name: Gilead Sciences / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Gilead Sciences Inc Stock
Gilead Sciences Inc gained 0.870% compared to yesterday.
The stock is an absolute favorite of our community with 46 Buy predictions and no Sell predictions.
With a target price of 120 € there is a slightly positive potential of 3.45% for Gilead Sciences Inc compared to the current price of 116.0 €.
So far the community has only identified positive things for Gilead Sciences Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Gilead Sciences Inc in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Gilead Sciences Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | 0.870% | 6.758% | 8.307% | 29.665% | 8.470% | 49.312% | 104.809% |
| Incyte Corp. | 0.190% | -5.745% | 0.841% | 24.819% | 2.470% | 10.840% | 4.227% |
| Regeneron Pharmaceuticals Inc. | 1.000% | 0.918% | -4.236% | -0.963% | -3.860% | -6.139% | 41.156% |
| Amgen Inc. | 0.650% | 2.352% | 3.735% | 11.086% | 4.087% | 24.059% | 37.742% |
Comments
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at UBS Group AG from $145.00 to $155.00. They now have a "buy" rating on the stock.
Show more
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at BMO Capital Markets from $135.00 to $150.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Rothschild & Co Redburn from $153.00 to $159.00. They now have a "buy" rating on the stock.
Show more
Ratings data for GILD provided by MarketBeat